- Trial phase
- Phase 1/2
- Time to market
- 5+ years (Phase 1/2; furthest Phase 2 efficacy portion ongoing; regulatory filing unlikely before 2028-2029 if successful)
- Why 4/10
- The next hard catalyst is Phase 2 efficacy data from the IOV-GM1-201 trial in previously treated advanced melanoma, originally guided for Q1 2026 but not yet prominently reported as of July 2026. The data may have been delayed or presented quietly. Because IOV-4001 is one of several pipeline programs at a company whose primary value driver is already-approved/commercialized Amtagvi, the impact score is capped at 4, a positive readout would boost the pipeline narrative but is not make-or-break for IOVA.
Watch for IOV-4001 Phase 2 efficacy data from the melanoma cohort of IOV-GM1-201, which was expected in early 2026 and may be reported later this year. Positive data would validate Iovance's next-generation TIL platform and could lift the stock, but IOVA's near-term value is primarily tied to Amtagvi commercial execution. The 2026 revenue guidance of $350M-$370M and Q2 earnings (around Aug 6, 2026) are more immediate catalysts.
Price Chart
Executive Summary
IOV-4001 is Iovance Biotherapeutics' first genetically modified tumor-infiltrating lymphocyte (TIL) therapy, using TALEN gene-editing (licensed from Cellectis) to knock out the PD-1 checkpoint gene. It is designed for patients with advanced melanoma and non-small cell lung cancer who have progressed on prior anti-PD-1 therapy. Currently in a Phase 1/2 trial, IOV-4001 is an early-stage pipeline asset at a company whose primary revenue driver is the already-approved TIL therapy Amtagvi (lifileucel), which generated ~$264M in full-year 2025 product revenue. IOVA has 13 Buy/Strong Buy ratings, 3 Hold, 0 Sell with a mean analyst price target of $8.80 (~177% upside from ~$4.31). The Phase 2 efficacy data, originally guided for Q1 2026, has not been prominently reported, suggesting possible delays.
How It Works
IOV-4001 is a personalized cell therapy made from a patient's own immune cells (T cells) that are extracted from their tumor, genetically modified in a lab using TALEN gene-editing technology to disable the PD-1 "off switch," multiplied into billions, and then infused back into the patient. This creates T cells that can recognize and attack the cancer without being suppressed by the tumor's PD-1/PD-L1 checkpoint pathway, essentially combining the benefits of cell therapy and immune checkpoint blockade in a single treatment.
Trial Status
First-in-human Phase 1/2 open-label study (IOV-GM1-201; NCT05361174) evaluating IOV-4001 in ~53 patients with unresectable/metastatic melanoma or Stage III/IV NSCLC. Phase 1 safety run-in assessed dose-limiting toxicities; Phase 2 efficacy portion (enrolling previously treated advanced melanoma and NSCLC) was described as "enrolling rapidly" in early 2025 with data originally anticipated for Q1 2026. As of July 2026, the latest corporate updates indicate the trial is ongoing without definitive topline data having been released.
The Two-Sided Case
Upcoming Catalysts
- Phase 2 efficacy data from IOV-GM1-201 trial in previously treated advanced melanoma (expected but delayed from Q1 2026)
- Q2 2026 earnings report (~Aug 6, 2026), Amtagvi revenue trajectory, pipeline updates, and any IOV-4001 data timing guidance
- Potential presentation of IOV-4001 data at a major medical conference in H2 2026
- NSCLC milestone: completion of enrollment in IOV-LUN-202 (lifileucel) with updated dataset
Source Filing
The SecBot filing or press-release report that triggered this drug report:
IOVANCE BIOTHERAPEUTICS, INC. 8-K IOVA ·Originating report